SZN-8143 / Surrozen - LARVOL DELTA

The Company continues to progress its lead candidates, SZN-8141 and SZN-8143, in retinal diseases and remains on track to submit an Investigational New Drug (IND) application for SZN-8141 in the second half of 2026 (GlobeNewswire) - "The Company presented evidence of preclinical efficacy of our novel bi-functional antibody SZN-8141 at its Poster Presentation during the Association for Research in Vision and Ophthalmology (2026 ARVO) in May 2026. By synergizing actions of Wnt activation and VEGF inhibition, SZN-8141 demonstrates superiority over monotherapies in preclinical models, suggesting the potential for improved outcomes compared to current therapies such as anti-VEGF standard of care."

IND • Preclinical • Age-related Macular Degeneration • Diabetic Macular Edema

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases (GlobeNewswire) - "Surrozen, Inc...today announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies. The Company also announced a private placement consisting of two tranches in aggregate up to $175 million in gross proceeds to fund multiple ophthalmology programs through initial Phase 1 safety, tolerability and efficacy studies...The two lead candidates for the treatment of retinopathies include SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6)...The Company will discontinue development of SZN-043 in severe alcohol associated hepatitis....The second closing is subject to the receipt of clearance from the FDA of the Company’s Investigational New Drug Application for SZN-8141, expected in 2026."

Discontinued • Financing • IND • Diabetic Macular Edema • Hepatology • Ophthalmology • Wet Age-related Macular Degeneration